TRACTATENBLAD
VAN HET
KONINKRIJK DER NEDERLANDEN
66 (1989) Nr. 31
A.

TITEL
Overeenkomst ter bestrijding van doping (met Bijlage);
Straatsburg, 16 november 1989
Voor een overzicht van de verdragsgegevens, zie verdragsnummer 003898 in de Verdragenbank.
B.

TEKST
De Commissie van Toezicht heeft op 18 december 2024, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, een wijziging van de Bijlage aangenomen. De Engelse tekst
1)
De Franse tekst is niet opgenomen.
van de wijziging luidt als volgt:

Anti-doping convention (ETS no. 135) – amendment to the appendix
(approved by the Monitoring Group by written procedure on 18 December 2024)
The 2025 Prohibited List – World Anti-Doping Code
Date of entry into force: 1 January 2025

Introduction
The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program.
The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2025.
The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.
Below are some terms used in this List of Prohibited Substances and Prohibited Methods.

Prohibited In-Competition
Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process.

Prohibited at all times
This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code.

Specified and non-Specified
As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.”

Substances of Abuse
Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”), tetrahydrocannabinol (THC).

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
S0.

NON-APPROVED SUBSTANCES
All prohibited substances in this class are prohibited at all times (in- and out-of-competition).
All prohibited substances in this class are Specified Substances
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.
This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).
S1.

ANABOLIC AGENTS
All prohibited substances in this class are prohibited at all times (in- and out-of-competition).
All prohibited substances in this class are non-Specified Substances.
Anabolic agents are prohibited.
S1.1.

ANABOLIC ANDROGENIC STEROIDS (AAS)
When administered exogenously, including but not limited to:
1-Androstenediol (5α-androst-1-ene-3β,17β-diol)
1-Androstenedione (5α-androst-1-ene-3,17-dione)
1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one)
1-Epiandrosterone (3β-hydroxy-5α-androst-1-ene-17-one)
1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one)
4-Androstenediol (androst-4-ene-3β,17β-diol);
4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)
5-Androstenedione (androst-5-ene-3,17-dione)
7α-Hydroxy-DHEA
7β-Hydroxy-DHEA
7-Keto-DHEA
11ß-Methyl-19-nortestosterone
17ɑ-methylepithiostanol (epistane)
19-Norandrostenediol (estr-4-ene-3,17-diol)
19-Norandrostenedione (estr-4-ene-3,17-dione)
Androst-4-ene-3,11,17-trione (11-ketoandrostenedione, adrenosterone)
Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one)
Androstenediol (androst-5-ene-3β,17β-diol)
Androstenedione (androst-4-ene-3,17-dione)
Bolasterone
Boldenone
Boldione (androsta-1,4-diene-3,17-dione)
Calusterone
Clostebol
Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en-20-yn-17α-ol)
Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol and 17ɑ-methyl-5a-androst-3-en-17ß-ol)
Dimethandrolone (7ɑ,11ß-Dimethyl-19-nortestosterone)
Drostanolone
Epiandrosterone (3β-hydroxy-5α-androstan-17-one)
Epi-dihydrotestosterone (17β-hydroxy-5β-androstan-3-one)
Epitestosterone
Ethylestrenol (19-norpregna-4-en-17α-ol)
Fluoxymesterone
Formebolone
Furazabol (17α-methyl [1,2,5]oxadiazolo[3’,4’:2,3]-5α-androstan-17β-ol)
Gestrinone
Mestanolone
Mesterolone
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
Metenolone
Methandriol
Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
Methylclostebol
Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one)
Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one)
Methyltestosterone
Metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one)
Mibolerone
Nandrolone (19-nortestosterone)
Norboletone
Norclostebol (4-chloro-17β-ol-estr-4-en-3-one)
Norethandrolone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prasterone (dehydroepiandrosterone,
DHEA, 3β-hydroxyandrost-5-en-17-one)
Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1’H-pyrazolo[3,4:2,3]-5α-androstane)
Quinbolone
Stanozolol
Stenbolone
Testosterone
Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
Tibolone
Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
Trestolone (7a-Methyl-19-nortestosterone, MENT)
and other substances with a similar chemical structure or similar biological effect(s).
S1.2.

OTHER ANABOLIC AGENTS
Including, but not limited to:
Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.
S2.

PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS
All prohibited substances in this class are prohibited at all times (in- and out-of-competition).
All prohibited substances in this class are non-Specified Substances
The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:
S2.1.

ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS
Including, but not limited to:
- S2.1.1
Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide).
- S2.1.2
Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.
- S2.1.3
GATA inhibitors, e.g. K-11706.
- S2.1.4
Transforming growth factor beta (TGF-β) signalling inhibitors, e.g. luspatercept; sotatercept.
- S2.1.5
Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).
S2.2.

PEPTIDE HORMONES AND THEIR RELEASING FACTORS
- S2.2.1
Testosterone-stimulating peptides in males including, but not limited to:
chorionic gonadotrophin (CG),
luteinizing hormone (LH),
gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin),
kisspeptin and its agonist analogues.
- S2.2.2
Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide.
- S2.2.3
Growth hormone (GH), its analogues and fragments including, but not limited to:
growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon
growth hormone fragments, e.g. AOD-9604 and hGH 176-191.
- S2.2.4
Growth hormone releasing factors, including, but not limited to:
growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin];
GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6].
S2.3.

GROWTH FACTORS AND GROWTH FACTOR MODULATORS
Including, but not limited to:
Fibroblast growth factors (FGFs)
Hepatocyte growth factor (HGF)
Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues
Mechano growth factors (MGFs)
Platelet-derived growth factor (PDGF)
Thymosin-β4 and its derivatives e.g. TB-500
Vascular endothelial growth factor (VEGF)
and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.
S3.

BETA-2 AGONISTS
All prohibited substances in this class are prohibited at all times (in- and out-of-competition).
All prohibited substances in this class are Specified Substances
All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to:
Arformoterol
Fenoterol
Formoterol
Higenamine
Indacaterol
Levosalbutamol
Olodaterol
Procaterol
Reproterol
Salbutamol
Salmeterol
Terbutaline
Tretoquinol (trimetoquinol)
Tulobuterol
Vilanterol
EXCEPTIONS
- • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;
- • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose;
- • Inhaled salmeterol: maximum 200 micrograms over 24 hours.
- • Inhaled vilanterol: maximum 25 micrograms over 24 hours.
NOTE
The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.
S4.

HORMONE AND METABOLIC MODULATORS
All prohibited substances in this class are prohibited at all times (in- and out-of-competition).
Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.
The following hormone and metabolic modulators are prohibited:
S4.1.

AROMATASE INHIBITORS
Including, but not limited to:
2-Androstenol (5α-androst-2-en-17-ol)
2-Androstenone (5α-androst-2-en-17-one)
3-Androstenol (5α-androst-3-en-17-ol)
3-Androstenone (5α-androst-3-en-17-one)
4-Androstene-3,6,17 trione (6-oxo)
Aminoglutethimide
Anastrozole
Androsta-1,4,6-triene-3,17-dione(androstatrienedione)
Androsta-3,5-diene-7,17-dione (arimistane)
Exemestane
Formestane
Letrozole
Testolactone
S4.2.

ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]
Including, but not limited to:
Bazedoxifene
Clomifene
Cyclofenil
Elacestrant
Fulvestrant
Ospemifene
Raloxifene
Tamoxifen
Toremifene
S4.3.

AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION
Including, but not limited, to:
Activin A-neutralising antibodies;
Activin receptor IIB competitors such as:
- – Decoy activin receptors (e.g. ACE-031);
Anti-activin receptor IIB antibodies (e.g. bimagrumab);
Myostatin inhibitors such as:
- – Agents reducing or ablating myostatin expression
- – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
- – Myostatin- or precursor-neutralising antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab).
S4.4.

METABOLIC MODULATORS
- S4.4.1
  - – Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c);
  - – Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) and;
  - – Rev-erbα agonists, e.g. SR9009, SR9011
- S4.4.2
Insulins and insulin-mimetics, e.g. S519, S597 S4.4.3 Meldonium
- S4.4.4
Trimetazidine
S5.

DIURETICS AND MASKING AGENTS
All prohibited substances in this class are prohibited at all times (in- and out-of-competition).
All prohibited substances in this class are Specified Substances
All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
Including, but not limited to:
- •
Diuretics such as:
Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene, xipamide;
- • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan;
- •
Plasma expanders by intravenous administration such as:
Albumin, dextran, hydroxyethyl starch, mannitol;
- • Desmopressin;
- • Probenecid;
and other substances with a similar chemical structure or similar biological effect(s).
EXCEPTIONS
- • Drospirenone; pamabrom; and topical ophtalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide);
- • Local administration of felypressin in dental anaesthesia.
NOTE
The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS
All prohibited methods are prohibited at all times (in- and out-of-competition).
All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods.
M1.

MANIPULATION OF BLOOD AND BLOOD COMPONENTS
The following are prohibited:
- M1.1.
The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
NOTE
Donation of blood or blood components, including by apheresis, is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates.
- M1.2.
Artificially enhancing the uptake, transport or delivery of oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.
- M1.3.
Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
M2.

CHEMICAL AND PHYSICAL MANIPULATION
The following are prohibited:
- M2.1.
Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.
Including, but not limited to:
Sample substitution and/or adulteration, e.g. addition of proteases to Sample.
- M2.2.
Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.
M3.

GENE AND CELL DOPING
The following, with the potential to enhance sport performance, are prohibited:
- M3.1.
The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.
- M3.2.
The use of normal or genetically modified cells.

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION
S6.

STIMULANTS
All prohibited substances in this class are prohibited in-competition.
All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances.
Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA/“ecstasy”)
All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include:
S6.A:

NON-SPECIFIED STIMULANTS
Adrafinil
Amfepramone
Amfetamine
Amfetaminil
Amiphenazole
Benfluorex
Benzylpiperazine
Bromantan
Clobenzorex
Cocaine
Cropropamide
Crotetamide
Fencamine
Fenetylline
Fenfluramine
Fenproporex
Fonturacetam [4-phenylpiracetam (carphedon)]
Furfenorex
Hydrafinil (fluorenol)
Lisdexamfetamine
Mefenorex
Mephentermine
Mesocarb
Metamfetamine(d-)
p-methylamfetamine
Modafinil
Norfenfluramine
Phendimetrazine
Phentermine
Prenylamine
Prolintane
A stimulant not expressly listed in this section is a Specified Substance.
S6.B:

SPECIFIED STIMULANTS
Including, but not limited to:
2-phenylpropan-1-amine (ß-methylphenylethyl-amine, BMPEA)
3-Methylhexan-2-amine (1,2-dimethylpentylamine)
4-Fluoromethylphenidate
4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexaneamine)
4-Methylpentan-2-amine (1,3-dimethylbutylamine)
5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA)
Benzfetamine
Cathine
2)
Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.
Cathinone and its analogues, e.g. mephedrone, methedrone, and α-pyrrolidinovalerophenone
Dimetamfetamine (dimethylamphetamine)
Ephedrine
3)
Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre.
Epinephrine
4)
Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.
(adrenaline)
Etamivan
Ethylphenidate
Etilamfetamine
Etilefrine
Famprofazone
Fenbutrazate
Fencamfamin
Heptaminol
Hydroxyamfetamine (parahydroxyamphetamine)
Isometheptene
Levmetamfetamine
Meclofenoxate
Methylenedioxymethamphetamine
Methylephedrine
5)
Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre.
Methylnaphthidate [(±)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate]
Methylphenidate
Midodrine
Nikethamide
Norfenefrine
Octodrine (1,5-dimethylhexylamine)
Octopamine
Oxilofrine (methylsynephrine)
Pemoline
Pentetrazol
Phenethylamine and its derivatives
Phenmetrazine
Phenpromethamine
Propylhexedrine
Pseudoephedrine
6)
Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.
Selegiline
Sibutramine
Solriamfetol
Strychnine
Tenamfetamine (methylenedioxyamphetamine)
Tesofensine
Tuaminoheptane
and other substances with a similar chemical structure or similar biological effect(s).
EXCEPTIONS
- • Clonidine, guanfacine;
- •
Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2025 Monitoring Program
7)
Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2025 Monitoring Program and are not considered Prohibited Substances.
.
S7.

NARCOTICS
All prohibited substances in this class are prohibited in-competition.
All prohibited substances in this class are Specified Substances.
Substance of Abuse in this section: diamorphine (heroin)
The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
Buprenorphine
Dextromoramide
Diamorphine (heroin)
Fentanyl and its derivatives
Hydromorphone
Methadone
Morphine
Nicomorphine
Oxycodone
Oxymorphone
Pentazocine
Pethidine
Tramadol
S8.

CANNABINOIDS
All prohibited substances in this class are prohibited in-competition.
All prohibited substances in this class are Specified Substances.
Substance of Abuse in this section: tetrahydrocannabinol (THC)
All natural and synthetic cannabinoids are prohibited, e.g.:
- • In cannabis (hashish, marijuana) and cannabis products
- • Natural and synthetic tetrahydrocannabinols (THCs)
- • Synthetic cannabinoids that mimic the effects of THC
EXCEPTIONS
- • Cannabidiol.
S9.

GLUCOCORTICOIDS
All prohibited substances in this class are prohibited in-competition.
All prohibited substances in this class are Specified Substances.
All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.
Including, but not limited to:
Beclometasone
Betamethasone
Budesonide
Ciclesonide
Cortisone
Deflazacort
Dexamethasone
Flunisolide
Fluocortolone
Fluticasone
Hydrocortisone
Methylprednisolone
Mometasone
Prednisolone
Prednisone
Triamcinolone acetonide
NOTE
Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications.

PROHIBITED IN PARTICULAR SPORTS.
P1.

BETA-BLOCKERS
All prohibited substances in this class are Specified Substances
Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated
8)
Also prohibited Out-of-Competition
.
- •
Archery (WA)
9)
Also prohibited Out-of-Competition
- • Automobile (FIA)
- • Billiards (all disciplines) (WCBS)
- • Darts (WDF)
- • Golf (IGF)
- • Mini-Golf (WMF)
- •
Shooting (ISSF, IPC)
10)
Also prohibited Out-of-Competition
- •
Underwater sports (CMAS)
11)
Also prohibited Out-of-Competition
in all subdisciplines of freediving, spearfishing and target shooting.
Including but not limited to:
Acebutolol
Alprenolol
Atenolol
Betaxolol;
Bisoprolol
Bunolol
Carteolol
Carvedilol
Celiprolol
Esmolol
Labetalol
Metipranolol;
Metoprolol
Nadolol
Nebivolol
Oxprenolol
Pindolol
Propranolol
Sotalol
Timolol
G.

INWERKINGTREDING
De wijziging van 18 december 2024 van de Bijlage bij de Overeenkomst is op 1 januari 2025 in werking getreden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.
Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese deel en het Caribische deel), Curaçao en Sint Maarten.
In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van 18 december 2024 van de Bijlage bij de Overeenkomst zal zijn bekendgemaakt in Nederland (het Europese deel en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.
Uitgegeven de twintigste februari 2025.
De Minister van Buitenlandse Zaken,
C.C.J.
VELDKAMP